Haemate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate is indicated for the management of bleeding disorders that involve a deficiency of factor VIII and von Willebrand factor.

• Treatment of acute bleeding episodes in patients with hemophilia A.
• Perioperative prophylaxis to prevent surgical bleeding in hemophilia A.
• Management of mucosal or gastrointestinal bleeding in von Willebrand disease.
• Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in severe hemophilia A.
• Replacement therapy for patients with combined factor VIII and von Willebrand factor deficiency.

Adverse reactions reported with Haemate vary in frequency and severity; they are categorized as common or serious.

Common

• Mild headache or fatigue.
• Transient fever, chills, or rigors.
• Local infusion site reactions such as erythema, swelling, or pain.
• Nausea or vomiting.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Anaphylactic or severe allergic reactions, including urticaria.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Renal impairment or hemolysis.

Before initiating Haemate therapy, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

• Assess for prior inhibitors to factor VIII or allergic reactions to plasma‑derived products.
• Perform baseline coagulation studies and periodic factor activity levels during treatment.
• Use caution in patients with a history of thrombosis or cardiovascular disease.
• Monitor for signs of infection, especially viral transmission, as the product is derived from human plasma.
• Adjust dosing in patients with renal or hepatic impairment as recommended by clinical guidelines.
• Educate patients on proper infusion techniques and the importance of reporting adverse symptoms promptly.

Haemate may interact with other medications that affect hemostasis or immune response; awareness of these interactions helps ensure safe use.

Avoid

• Concomitant use of other factor concentrates or bypassing agents without specialist guidance.
• Administration of pro‑thrombotic agents such as activated protein C or high‑dose estrogen therapy.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) may augment hemostatic effect and require dose adjustment.
• Immunosuppressive drugs can alter inhibitor development risk and should be monitored.
• Vaccinations, particularly live vaccines, should be timed appropriately around infusion sessions.
• Renal‑clearing medications such as aminoglycosides may affect drug clearance and need monitoring.